Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis

Interstitial Lung Disease Clinical Trial

— CHP-HRQOL  

Official title:

Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04273867
• Other study ID #: 19-05020233
• Status: Completed
• Start date: July 10, 2020
• Est. completion date: February 22, 2023

Study information

• Verified date: July 2023
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to administer and validate a disease specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP).

Description:

The objective of this study is to administer and validate a disease-specific health related quality of life (HRQOL) survey for patients with Chronic Hypersensitivity Pneumonitis (CHP). The survey items have been developed and revised from prior qualitative research with CHP patients. Potential participants will be recruited from WCMC, the Pulmonary Fibrosis Foundation (PFF) Registry and outside physician referral for the study. Participants will be asked to sign informed consent. At the initial visit participants will be asked to complete the survey and two additional PROs needed for concurrent validity testing. Participants will then be asked to complete the HRQOL survey under study a second time 2 weeks after the initial visit for test-re-test reliability testing. Pulmonary function testing and six minute walk test results will be collected. Pertinent demographic and clinical information will be collected from the patients and their medical records or registry data (if a PFF Registry participant). All information will be entered into a REDCap database for secure data management and storage. Psychometric testing will be performed on the overall survey instrument and the individual items in order to test validity and reliability. The goal is that the survey developed will be a reliable and valid measurement tool for use in both clinical practice and research settings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 22, 2023
• Est. primary completion date: February 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years old or older

2. Understand and sign the informed consent document

3. Documented diagnosis of HP made and confirmed at an ILD center via expert consensus or in multidisciplinary discussion a. Diagnosis based upon a minimum of a medical history, physical examination, pulmonary function testing, and computerized tomography (CT) scan. Pathology will be reviewed if available but is not required.

4. HP must be the primary pulmonary disease

5. Anticipated ability to complete follow up survey within 2 weeks of initial survey completion

6. Participants recruited from the PFF registry must have agreed to be contacted for ancillary research studies.

Exclusion Criteria:

1. Non-English Speaking (Patient must be able to speak and read English fluently but it does not have to be their primary language)

2. Inability to complete questionnaire due to cognitive impairment

3. Patients who have not been seen by or communicated with their provider in over 2 years

Related Conditions & MeSH terms

• Alveolitis, Extrinsic Allergic
• Chronic Hypersensitivity Pneumonitis
• Extrinsic Allergic Alveolitis
• Health-related Quality of Life
• Hypersensitivity
• Hypersensitivity Pneumonitis
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Pneumonia

Intervention

Other:
• Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument
This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.

Locations

Country	Name	City	State
United States	Weill Cornell Medicine	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Pulmonary Fibrosis Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis	The newly developed survey that is being validated consists of 42 items that assess the impact that Hypersensitivity Pneumonitis has on daily life for those who have the disease.	Day 0
Primary	Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the Short Form (SF-12) Survey	This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 12 items. The average score for this survey has been calibrated to 50 with scores below 50 indicating a below average score and scores above 50 indicating an above average score.	Day 0
Primary	Validation of a health-related quality of life instrument for patients with Chronic Hypersensitivity Pneumonitis by administering the King's Brief Interstitial Lung Disease Questionnaire	This survey will be used to assess the validity of the newly developed health-related quality of life instrument. This survey consists of 15 items and is scored from 0-100 with 100 indicating good health.	Day 0
Primary	Change in Health-related Quality of Life Assessment Score	The newly developed survey will be administered again in 2 weeks following the first assessment.	2 weeks following Day 0